Skip to main content
  1. Home
  2. Emerging Tech
  3. News

Passenger jet pilot reports a close encounter with a drone

Add as a preferred source on Google

The pilot of a passenger jet flying into Dallas Love Field on Friday reported seeing a drone within “a few hundred feet” during the approach. The unmanned aerial vehicle was also spotted from the air traffic control tower and authorities are currently trying to track down the pilot.

According to the Dallas Morning News, the Boeing 737 (Southwest Flight 28) was traveling from Houston to Dallas and saw the drone about a mile from the airport. The quadcopter was spotted by the aircraft’s left wing although the jet “landed without incident” and didn’t have to take any evasive action to avoid the drone.

Recommended Videos

Ground units and a helicopter were dispatched to try and locate the pilot, but so far the identity of the drone operator remains a mystery. “We’re concerned, because these are easily purchased devices, and they have pretty amazing capabilities,” said Mark Duebner, the director of aviation in Dallas

“I don’t think the average person understands the airspace limits around the airport, because they wouldn’t have reason to know them,” he added. “We need to do some campaigns to raise public awareness, though, because we don’t need these anywhere near the airport.”

The Federal Aviation Administration (FAA) is taking an “incremental approach” to drone regulations in the U.S. — drones used for commercial purposes, for example, currently require a special license while the FAA works out how it wants to manage their use more widely.

Rules for noncommercial drone use currently require that the UAVs are flown below 400 feet and remain within sight of the pilot. “Remain well clear of and do not interfere with manned aircraft operations,” add the regulations and “don’t fly within five miles of an airport unless you contact the airport and control tower before flying” — points that the drone pilot in Texas was obviously unaware of.

Via Ars Technica

David Nield
Former Contributor
Dave is a freelance journalist from Manchester in the north-west of England. He's been writing about technology since the…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more